3 patents
Utility
Treatment of cytokine release syndrome with GM-CSF antagonists
10 May 22
The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation.
Joe Pirrello, John Paolini, Eben Tessari
Filed: 19 May 21
Utility
Stable anti-OSMR antibody formulation
12 Oct 21
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
Filed: 26 Aug 19
Utility
Stable anti-OSMR antibody formulation
2 Dec 19
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
Filed: 10 Apr 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first